Neumora Therapeutics (NMRA) Interest Expenses (2025 - 2026)
Neumora Therapeutics (NMRA) recorded quarterly Interest Expenses of $1.9 million in Q1 2026, down 8.94% quarter-over-quarter from $2.0 million in Q4 2025.
Neumora Therapeutics (NMRA) Interest Expenses (2025 - 2026) Analysis & Trends
Neumora Therapeutics' Interest Expenses history runs 2 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Interest Expenses changed N/A year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $4.6 million (changed N/A YoY), while the FY2025 annual figure was $3.2 million, changed N/A from the prior year.
- Interest Expenses was $1.9 million for Q1 2026 at Neumora Therapeutics, down from $2.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.0 million in Q4 2025 to a low of $747000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -332,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 61,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -5.58 Mn |
| 10 | Neumora Therapeutics | 270.71 Mn | 270.71 Mn | - | 1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.85 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 747,000.00 |
| Sep 30, 2025 | 747,000.00 |